Skip to main content
. 2007 Mar 5;109(12):5160–5163. doi: 10.1182/blood-2006-12-063594

Table 1.

Patient characteristics and clinical outcome

UPN Age/Sex Clinical Stage Histology/Grade Prior Chemotherapy/Response* Time to vaccination (months)** Prevaccine Status Postvaccine Status (months)***
1 32/M IVA FL/2 PACE/PR 9 PR SD (22)#
2 56/F IVA FL/2 PACE/PR 10 PR PD (15)
3 33/M IVA FL/1 PACE/PR 8 PR PD (17)
4 42/M IVA FL/1 PACE/CR 83 PD## PD (10)
5 53/M IVA FL/1 PACE/CR 20 PD## CR (30+)###
6 53/F IVA FL/1 PACE/CR 12 PD## PD (12)
7 20/F IVA FL/1 PACE/PR 8 PD## PD (3)
8 60/M IVA FL/1 PACE/CR 15 PD## PD (8)
9 48/M IIIA FL/2 None n/a PD## PD (5)
10 44/M IIIA FL/1 None n/a PD## PD (3)
11 52/M IVA FL/2 None n/a PD## PD (2)

UPN indicates unique patient number; FL, follicular lymphoma; PACE, prednisone, doxorubicin, cyclophosphamide, and etoposide; PR, partial response; SD, stable disease; PD, progressive disease; CR, complete response.

*

Best response to chemotherapy

**

Time to vaccination from last chemotherapy

***

Months after starting vaccination.

#

Lost to follow-up

##

The duration of progressive disease varied from 6 to 12 months prior to vaccine administration

###

Remains in complete remission 44 months after completion of the vaccination.